Clinical Trial Update: A Study to Evaluate Whether Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease [Phase 2]

View source ↗

Summary

Phase 2 study assessing macitentan as a safety and efficacy treatment for heart failure with preserved ejection fraction and pulmonary vascular disease; results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Preserved Ejection Fraction

Drugs mentioned

• OPSUMIT (macitentan)

Snippet

Sponsor: Actelion | Conditions: Heart Failure With Preserved Ejection Fraction | Phase 2 | Status: COMPLETED | Results posted: 2022-04-04